BR112014013985A2 - formulações orais para tratamento de sobrecarga de metal - Google Patents

formulações orais para tratamento de sobrecarga de metal

Info

Publication number
BR112014013985A2
BR112014013985A2 BR112014013985A BR112014013985A BR112014013985A2 BR 112014013985 A2 BR112014013985 A2 BR 112014013985A2 BR 112014013985 A BR112014013985 A BR 112014013985A BR 112014013985 A BR112014013985 A BR 112014013985A BR 112014013985 A2 BR112014013985 A2 BR 112014013985A2
Authority
BR
Brazil
Prior art keywords
oral formulations
metal
treatment
metal overload
overload treatment
Prior art date
Application number
BR112014013985A
Other languages
English (en)
Portuguese (pt)
Inventor
Y Rienhoff Hugh Jr
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014013985(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of BR112014013985A2 publication Critical patent/BR112014013985A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112014013985A 2011-12-09 2012-12-07 formulações orais para tratamento de sobrecarga de metal BR112014013985A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568890P 2011-12-09 2011-12-09
US201161568914P 2011-12-09 2011-12-09
PCT/US2012/068432 WO2013086312A1 (en) 2011-12-09 2012-12-07 Oral formulations for treating metal overload

Publications (1)

Publication Number Publication Date
BR112014013985A2 true BR112014013985A2 (pt) 2017-06-13

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013985A BR112014013985A2 (pt) 2011-12-09 2012-12-07 formulações orais para tratamento de sobrecarga de metal

Country Status (9)

Country Link
US (1) US8993606B2 (enExample)
EP (1) EP2787994A4 (enExample)
JP (1) JP2015500294A (enExample)
AR (1) AR089122A1 (enExample)
AU (1) AU2012347595A1 (enExample)
BR (1) BR112014013985A2 (enExample)
CA (1) CA2857990A1 (enExample)
TW (1) TW201338777A (enExample)
WO (1) WO2013086312A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
AU2014228308A1 (en) 2013-03-15 2015-08-27 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
WO2015077655A1 (en) * 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
CA2984250A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
EP3999059A1 (en) 2019-07-19 2022-05-25 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)
WO2022157185A1 (en) 2021-01-20 2022-07-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107626A1 (en) 2005-04-04 2006-10-12 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
CA2680592C (en) 2007-03-15 2016-07-05 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
MY163516A (en) * 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CN102648189A (zh) 2009-07-27 2012-08-22 费罗金生物科学股份有限公司 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的前药
CN102574824B (zh) 2009-08-25 2016-04-27 佛罗里达大学研究基金会 去铁硫辛聚醚类似物及其用途
EP2566854A4 (en) 2010-05-04 2013-11-06 Shire Llc DESAZADESFERROTHIOCIN AND DEAZADESFERROTHIOCIN POLYETHER ANALOGS AS METAL CHELATORS

Also Published As

Publication number Publication date
CA2857990A1 (en) 2013-06-13
US8993606B2 (en) 2015-03-31
JP2015500294A (ja) 2015-01-05
AR089122A1 (es) 2014-07-30
WO2013086312A1 (en) 2013-06-13
EP2787994A4 (en) 2015-08-26
AU2012347595A1 (en) 2014-06-26
TW201338777A (zh) 2013-10-01
EP2787994A1 (en) 2014-10-15
US20130225645A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
IL284530A (en) RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases
HUE045629T2 (hu) Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
BR112014013985A2 (pt) formulações orais para tratamento de sobrecarga de metal
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
JO3091B1 (ar) مشتقات حمض 3- فنيل بروبيونيك متفرعة واستخداماتها
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
BR112015027055A8 (pt) bi-heteroarilas, usos das mesmas, e composição farmacêutica
BR112014030330A2 (pt) lentes oftálmicas levando em consideração a lateralidade do usuário
BR112013022052A2 (pt) ligantes antagonísticos de dr3
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
PH12013501882A1 (en) Antimicrobial agents
BR112015000329A2 (pt) formulações de diclofenac
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EP2709642A4 (en) THERAPEUTIC COMPOSITIONS OF CERTAIN HERBAL FORMULATIONS AND USES THEREOF
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
ECSP13012603A (es) Nueva formulacion del cetp(1)
EA201491581A1 (ru) Везикулярные композиции

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]